Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

COPD: Pathogenesis and Clinical Features

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...

Chronic Obstructive Pulmonary Disease-I: Introduction

Chronic Obstructive Pulmonary Disease-I: Introduction

Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.

Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies

Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies

Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History

COPD: Management Using Bronchodilators and Corticosteroids

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...

Chronic Obstructive Pulmonary Disease-V: Management

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation

Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.

Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.

Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The preclinical discovery and development of depemokimab for severe eosinophilic asthma.

Pulmonary pharmacology & therapeutics·2026

Same author

TQC3721: Expanding the Role of Dual Phosphodiesterase 3/4 Inhibition in COPD Management.

Chest·2026

Same author

Mucus plugs in COPD and cardiovascular mortality: An emerging risk pathway and the therapeutic potential of mucolytic strategies.

Respiratory medicine·2026

Same author

IL-1β Pathway Inhibition in Asthma and COPD: Strong Biological Rationale, Disappointing Clinical Trials, and Emerging New Opportunities.

Lung·2026

Same author

Respiratory health in a changing environment: environment-adaptive therapies and revised dosing strategies.

Expert review of respiratory medicine·2026

Same author

Redox signaling in chronic airway diseases: pathogenic mechanisms and therapeutic implications.

Frontiers in physiology·2026

Search research articles

Related Experiment Video

Updated: Aug 19, 2025

Assessment of Dependence in Activities of Daily Living Among Older Patients in an Acute Care Unit

Assessment of Dependence in Activities of Daily Living Among Older Patients in an Acute Care Unit

Published on: September 30, 2020

Clinically important deterioration: a composite tool for managing patients with COPD.

Mario Cazzola¹, Maria Gabriella Matera²

¹Unit of Respiratory Medicine, Department of Experimental Medicine, University of Rome 'Tor Vergata', Rome, Italy.

Respiratory Medicine

|November 26, 2022

Summary

Clinically important deterioration (CID) assessment aids COPD management. Dual bronchodilation is preferred over single therapy for reducing COPD progression, with triple therapy effective for high eosinophil counts.

More Related Videos

Author Spotlight: Evaluating the Therapeutic Efficacy of Moving Cupping Along Meridians for Acute Exacerbation of COPD

Author Spotlight: Evaluating the Therapeutic Efficacy of Moving Cupping Along Meridians for Acute Exacerbation of COPD

Published on: September 27, 2024

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

Related Experiment Videos

Last Updated: Aug 19, 2025

Assessment of Dependence in Activities of Daily Living Among Older Patients in an Acute Care Unit

Assessment of Dependence in Activities of Daily Living Among Older Patients in an Acute Care Unit

Published on: September 30, 2020

Author Spotlight: Evaluating the Therapeutic Efficacy of Moving Cupping Along Meridians for Acute Exacerbation of COPD

Author Spotlight: Evaluating the Therapeutic Efficacy of Moving Cupping Along Meridians for Acute Exacerbation of COPD

Published on: September 27, 2024

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

Area of Science:

Pulmonary Medicine
Respiratory Disease Research
Clinical Trial Analysis

Background:

Clinically important deterioration (CID) is a composite measure for assessing Chronic Obstructive Pulmonary Disease (COPD) progression.
CID offers a holistic patient assessment, improving clinical decision-making in COPD management.
Retrospective analyses of COPD trials highlight the significance of evaluating CID.

Purpose of the Study:

To evaluate the utility of Clinically Important Deterioration (CID) in assessing COPD progression.
To determine optimal therapeutic strategies for preventing CID in COPD patients.
To identify areas for improvement in the CID assessment tool.

Main Methods:

Post hoc analysis of clinical trials focused on COPD treatment.
Evaluation of treatment efficacy (dual bronchodilation vs. single bronchodilator, triple therapy) in preventing CID.
Assessment of initial CID thresholds (FEV1, SGRQ score, exacerbations) and their clinical relevance.

Main Results:

Dual bronchodilation is recommended over single bronchodilators to reduce COPD clinical deterioration.
Triple therapy, including inhaled corticosteroids, is effective in preventing CID, particularly in patients with high blood eosinophil counts.
Current CID thresholds (FEV1, SGRQ, exacerbations) were arbitrarily set and require refinement for better population-specific assessment.

Conclusions:

CID is a valuable tool for COPD management, guiding treatment choices.
Therapeutic strategies should be tailored based on CID assessment, favoring dual bronchodilation and considering triple therapy for specific patient groups.
Further prospective studies are essential to fully validate the CID instrument and refine its components for accurate COPD deterioration risk assessment.